Search our science

Search our scientific publications and resources
on rare bleeding disorders

Molecule
Study Phase
Content Type
Clear all filters

Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.

 

Search Results

We found 383 resources matching your search criteria

Abstract
Recombinant activated factor VII (rFVIIa) administered using an automated bolus infusion pump: Implications for the management of congenital haemophilia with inhibitors in the hospital setting
Rexen P, Taaftegaard Jensen J, Bjørn Schwerin N, Kozina E. Recombinant Activated Factor VII (rFVIIa) Administered Using an Automated Bolus Infusion Pump: Implications for the Management of Congenital Haemophilia With Inhibitors in the Hospital Setting. Haemophilia. 2019;25(Suppl. 1):35-188.
Poster
Recombinant Activated Factor VII (rFVIIa) Administered Using an Automated Bolus Infusion Pump: Implications for the Management of Congenital Haemophilia With Inhibitors in the Hospital Setting
Rexen P, Taaftegaard Jensen J, Bjørn Schwerin N, Kozina E. Recombinant Activated Factor VII (rFVIIa) Administered Using an Automated Bolus Infusion Pump: Implications for the Management of Congenital Haemophilia With Inhibitors in the Hospital Setting. Haemophilia. 2019;25((Suppl. 1)):155-6.
Primary manuscript
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, Ozelo M, Santagostino E, Suzuki T, Salek SZ, Korsholm L, Matytsina I, Tiede A. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian™2 extension trial. Haemophilia. 2018;24(6):e391-e394.
Secondary manuscript
Cost-Effectiveness of rFVIIa Versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico
del Carmen Rodríguez Zepeda M, González L, Bravo A, Pompa T, Silva S, Paredes R, García J, Ramos M, Wilkinson L, Lamotte M. Cost-Effectiveness of rFVIIa Versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico. Value Hlth Reg Issues. 2018;17:164-173.
Primary manuscript
Ranges and Drivers of Risk Associated With Sports and Recreational Activities in People With Hemophilia: Results of the Activity-Intensity-Risk (AIR) Consensus Survey of US Physical Therapists
Hernandez G, Baumann K, Knight S, Purrington H, Gilgannon M, Karelus M, Newman J, Tobase P, Mathew S Cooper DL. Ranges and Drivers of Risk Associated With Sports and Recreational Activities in People With Hemophilia: Results of the Activity-Intensity-Risk (AIR) Consensus Survey of US Physical Therapists. Haemophilia. 2018;24(S7):5-26.

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to www.novonordisk.com